genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2017
Actelion
Industry News
J&J Completes $30B Deal for Actelion, Which Spins Out Discovery, Early Pipeline
Industry News
Minerva Regains Global Rights to Insomnia Candidate from Janssen
Industry News
J&J to Buy Actelion in $30B Deal That Spins Out Independent Swiss R&D Firm
A-Lists
Top 25 Biotech Companies of 2015
News
Actelion Pays Auxilium $10M Up Front for Rights to Xiaflex in Specific Territories
Insights
FSPs Provide an Option to Traditional CRO Approach
Cancer
Pfizer, AstraZeneca, and Actelion Separately Report Phase III Trial Failures
Industry News
Actelion Pays €10M for Option to Buy Trophos for up to €195M
News
The Biggest R&D Collaboration Spenders in 2008
News
GSK Inks $3.3B Deal for Rights to Actelion’s Insomnia Drug
1
2
Page 1 of 2
Scroll Up
Scroll Up
